KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Current Deferred Revenue (2017 - 2025)

Historic Current Deferred Revenue for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to $20.8 million.

  • Aquestive Therapeutics' Current Deferred Revenue fell 262.27% to $20.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.8 million, marking a year-over-year decrease of 262.27%. This contributed to the annual value of $21.1 million for FY2024, which is 3788.94% down from last year.
  • According to the latest figures from Q3 2025, Aquestive Therapeutics' Current Deferred Revenue is $20.8 million, which was down 262.27% from $21.0 million recorded in Q2 2025.
  • Over the past 5 years, Aquestive Therapeutics' Current Deferred Revenue peaked at $37.8 million during Q1 2023, and registered a low of $765000.0 during Q4 2021.
  • For the 5-year period, Aquestive Therapeutics' Current Deferred Revenue averaged around $19.8 million, with its median value being $20.8 million (2025).
  • Per our database at Business Quant, Aquestive Therapeutics' Current Deferred Revenue soared by 214031.73% in 2023 and then plummeted by 3973.82% in 2024.
  • Over the past 5 years, Aquestive Therapeutics' Current Deferred Revenue (Quarter) stood at $765000.0 in 2021, then surged by 97.78% to $1.5 million in 2022, then soared by 2140.32% to $33.9 million in 2023, then tumbled by 37.89% to $21.1 million in 2024, then decreased by 1.42% to $20.8 million in 2025.
  • Its last three reported values are $20.8 million in Q3 2025, $21.0 million for Q2 2025, and $20.8 million during Q1 2025.